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Clinics and pathology 
Disease 
MKPL-1 cell line, established from a 66-year-old male 
patient with an acute megakaryoblastic leukemia (M7-
AML) and a karyotype apparently with -21,+3mar 
(Takeuchi et al., 1992), re-analysed for tyrosine kinase 
dysregulation (Gu et al., 2007). 
Epidemiology 
Only one case to date. 





From N-term to C-term, contains a BTB/POZ domain 
(mediates homomeric dimerization) and decamer repeat 
domains, responsible for multimerization/self-
association of the protein, RRM1 and RRM2 (RNA 
recognition motif) domains, an octamer repeat, a C2H2 
zinc finger, a nuclear localisation signal, and a G-patch 
(made of highly conserved glycines; may have RNA 
binding functions). RNA-binding protein. Binds 





Contains Ig-like domains (extracellular), a 
transmembrane domain, and a split tyrosine kinase 
domain (intracellular), from N-term to C-term. 
Transmembrane glycoprotein, receptor for the ligand  
colony stimulating factor-1 (CSF1). Upon binding of 
CSF1, CSF1R tyrosine phosphorylation is induced 
leading to RAS/RAF/MAPK, PI3K/AKT/mTOR and 
JAK/STAT (specifically STAT1, STAT3, and STAT5) 
pathways activation. CSF1R activation by CSF1 results 
in increased growth, proliferation and differentiation 
(Fischer et al., 2008). 




Fusion of RBM6 exon 2 to CSF1R exon 12; the 
reciprocal CSF1R-RBM6 was not detected. 
Fusion protein 
Description 
The RBM6-CSF1R fusion protein consists of the amino 
terminal 36 amino acids of RBM6, fused to the carboxy 
terminal 399 amino acids of CSF1R, including a 
polymerisation domain of RBM6, and the tyrosine 
kinase domain of CSF1R. 
Oncogenesis 
Constitutive tyrosine kinase activation. 
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